- Q1 2024 Curis Inc Earnings Call TranscriptMay 07, 2024$16.2 (+0.19%)Earnings
- Q4 2023 Curis Inc Earnings Call TranscriptFeb 08, 2024$10.65 (+13.42%)Earnings
- Q3 2023 Curis Inc Earnings Call TranscriptNov 02, 2023$4.51 (-4.25%)Earnings
- Q2 2023 Curis Inc Earnings Call TranscriptAug 03, 2023$15.42 (-2.98%)Earnings
- Q1 2023 Curis Inc Earnings Call TranscriptMay 04, 2023$16.76 (+3.48%)Earnings
- Q4 2022 Curis Inc Earnings Call TranscriptMar 13, 2023$11.51 (-8.40%)Earnings
- Curis Inc to Discuss Updated Emavusertib Clinical Data Call TranscriptDec 12, 2022
- Q3 2022 Curis Inc Earnings Call TranscriptNov 09, 2022$14.44 (-7.44%)Earnings
- Q2 2022 Curis Inc Earnings Call TranscriptAug 04, 2022$19.78 (+0.91%)Earnings
- Q1 2022 Curis Inc Earnings Call TranscriptMay 05, 2022$18.2 (-9.00%)Earnings
- Curis Inc at Needham Healthcare Conference (Virtual) - On-Demand TranscriptApr 12, 2022
- Q4 2021 Curis Inc Earnings Call TranscriptFeb 24, 2022$63.4 (+8.19%)Earnings
- Curis Inc to Discuss Positive Updated Clinical Data on Phase 1/2 Monotherapy Study of CA-4948 and Initial Clinical Data from Phase 1 Study of CI-8993 Call TranscriptJan 06, 2022
- Q3 2021 Curis Inc Earnings Call TranscriptNov 09, 2021$114.4 (-4.83%)Earnings
- Curis Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- Curis Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Curis Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Curis Inc Earnings Call TranscriptAug 03, 2021$139.8 (-9.46%)Earnings
- Curis Inc to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA Virtual Congress TranscriptJun 11, 2021
- Curis Inc Annual Shareholders Meeting TranscriptMay 27, 2021
- Q1 2021 Curis Inc Earnings Call TranscriptMay 12, 2021$325.4 (+65.51%)Earnings
- Q4 2020 Curis Inc Earnings Call TranscriptMar 16, 2021$211 (-4.26%)Earnings
- Curis Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-recorded TranscriptMar 09, 2021
- Curis Inc Virtual KOL Event - Reviewing CA-4948 Clinical Data in NHL & AML/MDS TranscriptDec 08, 2020
- Q3 2020 Curis Inc Earnings Call TranscriptNov 10, 2020$22.8 (+5.56%)Earnings
- Q2 2020 Curis Inc Earnings Call TranscriptAug 04, 2020$26.4 (+10.92%)Earnings
- Curis Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q1 2020 Curis Inc Earnings Call TranscriptMay 12, 2020$17.51 (+1.70%)Earnings
- Curis Inc at Needham Healthcare Conference TranscriptApr 14, 2020
- Q4 2019 Curis Inc Earnings Call TranscriptMar 19, 2020$14.73 (+1.94%)Earnings
- Curis Inc Corporate Call TranscriptDec 06, 2019
- Q3 2019 Curis Inc Earnings Call TranscriptNov 05, 2019$39 (-19.75%)Earnings
- Q2 2019 Curis Inc Earnings Call TranscriptAug 06, 2019$46.4 (+0.87%)Earnings
- Q1 2019 Curis Inc Earnings Call TranscriptMay 14, 2019$38.2 (+3.24%)Earnings
- Q4 2018 Curis Inc Earnings Call TranscriptMar 26, 2019$40.2 (+6.35%)Earnings
- Curis Inc at Cowen Health Care Conference TranscriptMar 13, 2019
Curis Inc at Cowen Health Care Conference Transcript
Good morning. I am CJ Zopf, a member of the biotech equity research team here at Cowen. I'm very pleased to introduce our next presenting company, Curis. Over the past year we've seen a shift in sentiment from the excitement around the all-encompassing possibilities of immuno-oncology to a more sober view that targeted agents with clearly defined patient populations offer a straightforward path to building value.
So Curis has taken several approaches to targeted therapies in selected populations, both for heme malignancies and solid tumors, which does also include their rare breed oral checkpoint inhibitor, which happens also to be a bispecific and thus maintains that selective population appeal. So here to present an update on the Company, I'm pleased to introduce James Dentzer, President and CEO of Curis.
Thank you very much. Welcome to the conference. I'm on slide 2 of the corporate presentation; obviously forward-looking statements. Everything we say here is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)